25,176 Shares in Aadi Bioscience, Inc. (NASDAQ:AADI) Acquired by Point72 Asia Singapore Pte. Ltd.

Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Aadi Bioscience, Inc. (NASDAQ:AADI) in the second quarter, HoldingsChannel.com reports. The firm bought 25,176 shares of the company’s stock, valued at approximately $37,000.

Separately, Marquette Asset Management LLC purchased a new stake in shares of Aadi Bioscience during the 1st quarter worth $135,000. Hedge funds and other institutional investors own 52.08% of the company’s stock.

Insider Buying and Selling at Aadi Bioscience

In other news, Chairman Neil Desai sold 40,000 shares of the stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $1.71, for a total transaction of $68,400.00. Following the sale, the chairman now directly owns 1,171,543 shares of the company’s stock, valued at approximately $2,003,338.53. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Over the last quarter, insiders sold 61,067 shares of company stock valued at $99,096. Corporate insiders own 37.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have commented on AADI shares. Jefferies Financial Group cut shares of Aadi Bioscience from a “buy” rating to a “hold” rating and lowered their price target for the company from $11.00 to $1.50 in a report on Wednesday, August 21st. Piper Sandler downgraded shares of Aadi Bioscience from an “overweight” rating to a “neutral” rating and lowered their target price for the company from $5.00 to $1.75 in a research note on Tuesday, August 27th. TD Cowen downgraded Aadi Bioscience from a “buy” rating to a “hold” rating in a research report on Wednesday, August 21st. HC Wainwright reiterated a “neutral” rating on shares of Aadi Bioscience in a research note on Wednesday, August 21st. Finally, Piper Sandler Companies lowered shares of Aadi Bioscience from an “overweight” rating to a “neutral” rating and set a $1.75 price objective for the company. in a research report on Tuesday, August 27th. Five investment analysts have rated the stock with a hold rating, Based on data from MarketBeat, Aadi Bioscience has a consensus rating of “Hold” and an average price target of $10.25.

Aadi Bioscience Price Performance

NASDAQ:AADI opened at $2.06 on Tuesday. The company’s fifty day moving average price is $1.66 and its 200-day moving average price is $1.77. Aadi Bioscience, Inc. has a 1-year low of $1.21 and a 1-year high of $5.70. The firm has a market capitalization of $50.58 million, a P/E ratio of -0.81 and a beta of 0.69.

Aadi Bioscience (NASDAQ:AADI) last issued its earnings results on Wednesday, August 7th. The company reported ($0.54) EPS for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.17. Aadi Bioscience had a negative return on equity of 66.67% and a negative net margin of 274.77%. The firm had revenue of $6.18 million for the quarter, compared to the consensus estimate of $6.33 million. During the same quarter in the prior year, the business earned ($0.67) earnings per share. Equities analysts anticipate that Aadi Bioscience, Inc. will post -2.02 EPS for the current fiscal year.

About Aadi Bioscience

Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.